Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
10027
Yasuyuki Okada, Tetsuo Kimura, Tadahiko Nakagawa, Koichi Okamoto, Akira Fukuya, Takahiro Goji, Shota Fujimoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Tsuji, Toshiya Okahisa, Tetsuji Takayama
EGFR Downregulation After Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal CancerMol Cancer Res
2017
15(10):1445-1454
PubMed ID: 28698359
DOI: 10.1158/1541-7786.MCR-16-0383
7823
Matsuo T, Nishizuka SS, Ishida K, Iwaya T, Ikeda M, Wakabayashi G.
Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models.BMC Res Notes
2011
4:140
PubMed ID: 21554739
DOI: 10.1186/1756-0500-4-140
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x